Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors

被引：0
|
作者：
von Mehren, M.
Britten, C.
Lear, K.
Camidge, D. R.
Wainberg, Z. A.
Pieslor, P. C.
Darif, M.
Harris, S.
Balogh, K.
Leong, S.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Calif Los Angeles, Clin Res Unit, Los Angeles, CA USA
[3] Univ Colorado Denver, Aurora, CO USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] Biogen Idec Inc, San Diego, CA USA
[6] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2612
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in patients with relapsed or refractory solid tumours
    von Mehren, M.
    Britten, C.
    Piesolor, P.
    Balogh, K.
    Bartok, A.
    Harris, S.
    Li, X.
    Galluppi, J.
    Barton, J.
    Leong, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 128 - 128
  • [2] A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
    von Mehren, Margaret
    Britten, Carolyn D.
    Pieslor, Peter
    Saville, Wayne
    Vassos, Artemios
    Harris, Sarah
    Galluppi, Gerald R.
    Darif, Mohamed
    Wainberg, Zev A.
    Cohen, Roger B.
    Leong, Stephen
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 518 - 525
  • [3] A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
    Margaret von Mehren
    Carolyn D. Britten
    Peter Pieslor
    Wayne Saville
    Artemios Vassos
    Sarah Harris
    Gerald R. Galluppi
    Mohamed Darif
    Zev A. Wainberg
    Roger B. Cohen
    Stephen Leong
    Investigational New Drugs, 2014, 32 : 518 - 525
  • [4] Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors
    Haluska, P.
    Shaw, H.
    Batzel, G. N.
    Molife, L. R.
    Adjei, A. A.
    Yap, T. A.
    Roberts, M. L.
    Gualberto, A.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
    Saif, Muhammad Wasif
    Takimoto, Chris
    Mita, Monica
    Banerji, Udai
    Lamanna, Nicole
    Castro, Januario
    O'Brien, Susan
    Stogard, Christopher
    Von Hoff, Daniel
    CLINICAL CANCER RESEARCH, 2014, 20 (02) : 445 - 455
  • [6] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [7] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [8] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [9] A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
    Becerra, Carlos R.
    Conkling, Paul
    Vogelzang, Nicholas
    Wu, Hilary
    Hong, Shengyan
    Narwal, Rajesh
    Liang, Meina
    Tavakkoli, Fatemeh
    Pandya, Naimish
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 917 - 925
  • [10] A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
    Carlos R. Becerra
    Paul Conkling
    Nicholas Vogelzang
    Hilary Wu
    Shengyan Hong
    Rajesh Narwal
    Meina Liang
    Fatemeh Tavakkoli
    Naimish Pandya
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 917 - 925
12345